

Endovascular Pharmacology Chart

Drug Name	Trade Names	Manufacturer	Drug Type	Primary Use	Mechanism
Heparin	(many)	N/A	Anticoagulant	Stroke Prevention	Inhibits Clotting of Blood <i>In Vivo</i> via Action on Antithrombin III
Enoxaparin Sodium (low-molecular-weight heparin [LMWH])	Lovenox	Aventis	Anticoagulant	Antithrombotic or Clot-Preventing	Intrinsic Cascade Inhibition
Fondaparinux Sodium	Arixtra	GlaxoSmithKline	Anticoagulant	Deep Vein Thrombosis	Factor Xa Inhibition
Bivalirudin	Angiomax	The Medicines Company	Anticoagulant	Heparin Substitute for Heparin-Intolerant Patients	Direct Thrombin Inhibition
Lepirudin	Refludan	Berlex	Anticoagulant	Heparin Substitute for Heparin-Intolerant Patients	Direct Thrombin Inhibition
Argatroban	Argatroban	GlaxoSmithKline/Texas Biotechnology Corporation	Anticoagulant	Heparin-Induced Thrombocytopenia	Direct Thrombin Inhibition
Dalteparin Sodium Injection	Fragmin	Pfizer	LMWH	Unstable Angina or Non-Q-Wave Myocardial Infarction	Factor Xa Inhibition
Warfarin	Coumadin	Bristol Myers Squibb	Anticoagulant	Stroke Prevention, Myocardial Infarction, Deep Vein Thrombosis, Other Clot Problems	Reduces the Ability of the Liver to Use Vitamin K to Make Blood Clotting Proteins
Acetylsalicylic Acid, ASA	Aspirin	Bayer	Antiplatelet	Stroke Prevention	Thromboxane Inhibitor
Clopidogrel	Plavix	Bristol Myers Squibb-Sanofi	Antiplatelet	Stroke Prevention	Inhibitor of Adenosine Diphosphate-Mediated Platelet Aggregation
Dipyridamole	Aggrenox, Persantine	Boehringer Ingelheim Pharmaceuticals	Antiplatelet	Stroke Prevention	Stimulates Prostacycline Production
Ticlopidine	Ticlid	Roche Pharmaceuticals	Antiplatelet	Stroke Prevention	Stimulates Prostacycline Production
Abciximab	ReoPro	Lilly/Centocor	IIb/IIIa Inhibitor	Cardiac Ischemia	Chimeric Monoclonal Antibody
Trofiban	Aggrastat	Merck or Guilford Pharmaceuticals	IIb/IIIa Inhibitor	Acute Coronary Syndrome	Tyrosine Derivative That Fits Into RGD Sequence of GP IIb/IIIa
Eptifibatide	Integrelin	Millennium Pharmaceuticals, Inc., and Schering-Plough Corporation	IIb/IIIa Inhibitor	Acute Coronary Syndrome	Cyclic Heptapeptide That Fits Into RGD Sequence of GP IIb/IIIa

Drug Name	Trade Names	Manufacturer	Drug Type	Primary Use	Mechanism
Atorvastatin	Lipitor	Pfizer	Statin	Lowering Cholesterol	HMG CoA Reductase Inhibitor
Fluvastatin	Lescol	Novartis	Statin	Lowering Cholesterol	HMG CoA Reductase Inhibitor
Lovastatin	Mevacor	Merck	Statin	Lowering Cholesterol	HMG CoA Reductase Inhibitor
	Altocor	Andrx			
Rosuvastatin Calcium	Crestor	AstraZeneca	Statin	Lowering Cholesterol	HMG CoA Reductase Inhibitor
Pravastatin Sodium	Pravachol	Bristol Myers Squibb	Statin	Heart Disease	HMG CoA Reductase Inhibitor
Simvastatin	Zocor	Merck	Statin	High Triglyceride Levels	HMG CoA Reductase Inhibitor
Simvastatin/Ezetimibe	Vytorin	Merck/Schering-Plough	Combination of Statin and Zetia	Hypercholesterolemia	Combination Product Containing HMG CoA Reductase Inhibitor + Calcium-Channel Antagonist
Amlodipine/Atorvastatin	Caduet	Pfizer	Combination of a Calcium-Channel Blocker With a Statin	Hypertension/Angina	Combination product Containing HMG CoA Reductase Inhibitor + Calcium-Channel Antagonist
Streptokinase	Streptase	Aventis	Fibrinolytic	Thromboembolic Disorders	Plasminogen Activator
Alteplase	Activase	Genentech	Fibrinolytic	Thromboembolic Disorders	Tissue Plasminogen Activator
Anistreplase	Eminase	Roberts Pharmaceuticals Corporation	Fibrinolytic	Acute Myocardial Infarction	Consists of the Lysform of Plasminogen and Streptokinase
Urokinase	Abbokinase	Abbott Laboratories	Fibrinolytic	Thromboembolic Disorders	Converts Plasminogen to Plasmin
Tenecteplase	TNKase	Genentech	Fibrinolytic	Acute Myocardial Infarction	Recombinant Tissue Plasminogen Activator (re-PA)
	Alfimeprase*	Nuvelo	Fibrinolytic	Peripheral Arterial Occlusion	Proteolytically Cleaves Both α and β Chains of Fibrin
Reteplase	Retevase	Scios	Fibrinolytic	Acute Myocardial Infarction	Converts Plasminogen to Plasmin
Ezetimibe	Zetia	Merck	Lipid Lowering	Lowering Cholesterol	Reduced Cholesterol Absorption From Gut
Nicardipine Hydrochloride	Cardene I.V.	EST Pharma	Calcium-Channel Blocker	Antihypertension	Dihydropyridine Calcium-Channel Blocker

*Currently in phase III clinical trials.